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ABSTRACT
We have recently shown that chronic fluoxetine treatment acted significantly increasing plasma 
norepinephrine and epinephrine concentrations both in control and chronically stressed adult male rats. 
However, possible effects of fluoxetine on catecholamine synthesis and re-uptake in adrenal medulla 
have been largely unknown. In the present study the effects of chronic fluoxetine treatment on tyrosine 
hydroxylase, a rate-limiting enzyme in catecholamine synthesis, as well as a norepinephrine transporter 
and vesicular monoamine transporter 2 gene expressions in adrenal medulla of animals exposed to chronic 
unpredictable mild stress (CUMS) for 4 weeks, were investigated. Gene expression analyses were performed 
using a real-time quantitative reverse transcription-PCR. Chronically stressed animals had increased 
tyrosine hydroxylase mRNA levels and decreased expression of both transporters. Fluoxetine increased 
tyrosine hydroxylase and decreased norepinephrine transporter gene expression in both unstressed and 
CUMS rats. These findings suggest that chronic fluoxetine treatment increased plasma catecholamine 
levels by affecting opposing changes in catecholamine synthesis and uptake.
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INTRODUCTION
The syndrome of major depression, particularly the 
melancholic type, potentially reflects dysregulation 
of the stress response (Chrousos and Gold 1998). 
The body responds to stress by activating the 
sympathoadrenal system and secreting epinephrine 
(E) and norepinephrine (NE) in the "fight-or-
flight" response (Cannon 1929). Elevated levels 
of catecholamines were also detected in patients 
with signs of depression (Hamer et al. 2007). 
Increased release of catecholamines during stress 
could result from the changes in catecholamine 
synthesis, storage and/or release in adrenal 
medulla. Tyrosine hydroxylase (TH) is a rate-
limiting enzyme in catecholamine biosynthetic 
process. Catecholamines are stored in secretory 
granules of adrenal chromaffin cells and released 
by regulated exocytosis. Two membrane carriers 
are involved in their subsequent reuptake and 
storage. The antidepressant- and cocaine-sensitive 
Na+, Cl--dependent norepinephrine transporter 
(NET) functions at the plasma membrane, mediates 
both the clearance of catecholamines and their 
recovery into the vesicles for subsequent re-use. 
Immunocytochemistry of rat adrenal tissue showed 
that NET staining was co-localized with TH in 
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medullary chromaffin cells (Kippenberger et al. 
1999). The uptake of monoamines from the cytoplasm 
into secretory granules is mediated by vesicular 
monoamine transporters (VMATs) and requires an 
ATPase-generated proton gradient (Erickson et al. 
1996, Eiden 2000). Several studies indicate that 
VMATs play a critical role not only in sorting, storing 
and releasing of monoamines, but also in fine-tuning 
of neuronal and endocrine informational output 
(Henry et al. 1994, Eiden et al. 2004). Two isoforms 
of the vesicular monoamine transporter (VMAT1 and 
VMAT2) have been characterized in rodent tissue 
(Erickson et al. 1992). VMAT1 is widely expressed 
in all adrenal chromaffin cells, while VMAT2 is co-
localized with TH enzyme (Tillinger et al. 2010). 
A subpopulation of chromogranin A -expressing 
chromaffin cells of the adrenal medulla also express 
VMAT2 (Weihe et al. 1994). Chromogranins 
are highly efficient systems directly involved in 
monoamine accumulation and in the exocytotic 
release of catecholamines (Borges et al. 2010). 
Numerous authors observed the changes in 
the synthesis of catecholamines in the brain after 
fluoxetine treatment, but the data on the effect 
of this drug on catecholamine synthesis in the 
adrenal glands, are sparse. While administration of 
tricyclic antidepressants causes decrease (Zavosh 
et al. 1999) or in contrast, increase of NET mRNA 
(Szot et al. 1993), SSRI antidepressants including 
fluoxetine have been reported to express no effect 
on NET mRNA expression (Benmansour et al. 
2004, Shinkai et al. 2005). Blardi et al. (2005) 
detected increased levels of catecholamines in 
depressed patients receiving fluoxetine (SSRI) for 
40 days. We have also found that chronic fluoxetine 
treatment leads to a marked increase in the amount 
of plasma catecholamines both in control and 
stressed rats (Dronjak et al. 2007). 
These results indicated the need to explore 
possible effects of fluoxetine on adrenal function 
using a chronic unpredictable mild stress (CUMS) 
paradigm in rats. The CUMS model was chosen 
because it induces many behavioral and biochemical 
characteristics that are similar to human depression, 
including anhedonia, reduced body weight and 
glucocorticoid hypersecretion (Willner et al. 1992, 
Papp et al. 1994, Dronjak et al. 2007). All these 
symptoms are reversed by chronic antidepressant 
treatment, indicating that this model has good 
predictive validity (Muscat et al. 1992). In order to 
examine whether the effects of fluoxetine on plasma 
catecholamine levels could be due to changes in 
their synthesis and/or release in adrenal medulla, the 
present study was undertaken to determine differences 
in TH, VMAT2 and NET gene expression in control 
and stressed rats after chronic fluoxetine treatment.
MATERIALS AND METHODS
ANIMALS
Adult Wistar male rats weighing 280-320g at 
the onset of experiments and maintained in a 
temperature-controlled room (21±1.0°C) and 
12h/12h light/dark cycle, were used. The care was 
taken to minimize the pain and discomfort of the 
animals according to the recommendations of 
the Ethical Committee of the "Vinca" Institute, 
Belgrade, which are in accordance with the Guide for 
Care and Use of Laboratory Animals of the National 
Institute of Health, Bethesda, MD, U.S.A. Fluoxetine 
(fluxilan®, Aeigis LTD, Cyprus) dissolved in sterile 
water and sonicated for approximately 10 min, was 
prepared ex tempore. Animals that were subjected 
to CUMS, according to method by Grippo et al. 
(2002), received daily injections of vehicle (sterile 
water) or fluoxetine (10 mg/kg) by i.p. route 
during 4 weeks. The fluoxetine dose was selected 
based upon the work of Reneric et al. (2002) and 
our previous study (Spasojevic et al. 2008). The 
control group was also receiving daily injections of 
vehicle. Upon completion of 4 weeks, the animals 
exposed to CUMS and controls were decapitated, 
the adrenal medulla rapidly dissected, frozen in 
liquid nitrogen and stored at − 70°C until analyzed. 
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RNA ISOLATION AND CDNA SYNTHESIS
Total RNAs were isolated using TRIZOL reagent 
(Invitrogen, CA, U.S.A.). Reverse transcription 
was performed using Ready-To-Go You-Prime 
First-Strand Bead (AP, Biotech) and pd (N)6 primer 
according to manufacturer’s protocol.
REAL-TIME RT-PCR
TaqMan PCR assays were carried out using Assay-
on-Demand Gene Expression Products (Applied 
Biosystems, USA) for TH (ID:Rn00562500-m1), 
NET (ID: Rn00580207_m1) and VMAT2 (ID: 
Rn00564688_m1). The reactions were performed 
in a 25 μl reaction mixture containing 1x TaqMan 
Universal Master Mix with AmpErase UNG, 
1x Assay Mix (Applied Biosystems) and cDNA 
template (10 ng of RNA converted to cDNA). PCR 
reactions were performed in the ABI Prism 7000 
Sequence Detection System at 50°C for 2 min, 
95°C for 10 min, followed by 40 cycles at 95°C for 
15 sec and 60°C for 1 min. A reference, endogenous 
control, was included in each analysis to correct 
the differences in the inter-assay amplification 
efficiency and all transcripts were normalized to 
cyclophyline A (ID:Rn 00690933) expression. 
Quantification was done using the 2-ΔΔCt method 
according to Livak and Schmittgen (2001).
STATISTICAL ANALYSIS
The results are reported as means ± S.E.M. 
Significance of the differences between the 
groups in gene expression levels of the examined 
catecholamine synthesising enzyme and transporters 
were estimated by Two-way ANOVA test, followed 
by the Tukey post hoc test. Statistical significance 
was accepted at p<0.05.
RESULTS
The exposure of rats to CUMS displayed low, 
although significant rise of 43% (p<0.05) in TH 
mRNA levels (Fig.1). Fluoxetine treatment also 
significantly increased TH mRNA expression both 
in control and stressed animals (by 43% and 34% 
respectively, p<0.05) in comparison to vehicle group.
Figure 1 - Effect of chronic treatment with fluoxetine on tyrosine hydroxylase (TH) mRNA levels in adrenal medulla of rats 
exposed to CUMS for 4 weeks. The values are means ±S.E.M. of 6-8 rats. Statistical significance: # p< 0.05 CUMS vs. unstressed 
control; * p<0.05 placebo vs. fluoxetine (Tukey test). The final result was expressed as fold change relative to the calibrator and 
normalized to cyclophyline A.
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Analysis of the data also displayed a significant 
chronic stress-related change (F(1,16) = 18.98, 
p<0.001) in VMAT2 mRNA levels. VMAT2 mRNA 
expression in medulla was decreased by 41% 
(p<0.01) after exposure of animals to CUMS, while 
fluoxetine expressed no effect (Fig. 2).
The results presented in Fig. 3. indicate a major 
influence of CUMS (F(1,16) = 17.94, p<0.001) on 
NET mRNA levels in the medulla. Post-hoc analysis 
demonstrated a significant decrease in stressed rats 
(by 41%, p < 0.05) in comparison to the controls. 
Long-term administration of the antidepressant 
altered NET mRNA content (F(1,16) = 20.72, p < 
0.001) (Fig. 3). Fluoxetine significantly diminished 
NET mRNA levels both in control and stressed rats 
(by 43%, p<0.01 and 50%, p<0.05, respectively).
Figure 2 - Effect of chronic treatment with fluoxetine on vesicular monoamine transporter 2 (VMAT2) mRNA levels in adrenal 
medulla of rats exposed to CUMS for 4 weeks. The values are means ±S.E.M. of 6-8 rats. Statistical significance: # p< 0.05; 
## p<0.01 CUMS vs. unstressed control (Tukey test). The final result was expressed as fold change relative to the calibrator and 
normalized to cyclophyline A.
Figure 3 - Effect of chronic treatment with fluoxetine on norepinephrine transporter (NET) mRNA levels in adrenal medulla of rats 
exposed to CUMS for 4 weeks. The values are means ±S.E.M. of 6-8 rats. Statistical significance: # p< 0.05; ## p<0.01 CUMS vs. 
unstressed control; * p<0.05, ** p<0.01 placebo vs. fluoxetine (Tukey test). The final result was expressed as fold change relative 
to the calibrator and normalized to cyclophyline A.
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DISCUSSION
In the present study, the effects of fluoxetine 
a widely used antidepressant on the levels of 
mRNAs encoding TH, a rate-limiting enzyme in 
catecholamine biosynthesis and two transporters 
NET and VMAT2 in adrenal medulla of CUMS rats, 
were examined. CUMS led to increased TH mRNA 
levels in the adrenal medulla. Similar to our results, 
Serova et al. (1998) had previously found elevated 
basal levels of TH mRNA in the adrenal medulla in 
Flinder's Sensitive Line (FSL), a genetic rat model 
of depression. Numerous authors have confirmed 
corticosterone regulation of TH mRNA (Kumai et al. 
2000, Tank et al. 1986). Animals exposed to CUMS 
were shown to have elevated plasma corticosterone 
levels (Dronjak et al. 2007), which could be the cause 
of the observed changes in the TH gene expression. 
Among SSRIs, fluoxetine uniquely increased extra-
cellular NE and serotonin (5-HT) levels (Pozzi et al. 
1999, Bymaster et al. 2002). According to Brady et 
al. (1992) and Heydendael and Jacobson (2010) this 
antidepressant stimulates the synthesis of NE in the 
brain by increasing TH mRNA levels. Our results also 
demonstrated that repeated fluoxetine administration 
led to increased expression of TH mRNAs in the 
adrenal medulla. Thome et al. (2000) reported that 
chronic treatment of rats with a number of clinically 
effective antidepressants significantly increased 
cAMP-controlled gene transcription, as well as 
phosphorylation (and activation) of the transcription 
factor, a cAMP response element binding protein 
(CREB), in several brain regions. Fluoxetine was 
shown to increase cAMP levels (Edgar et al. 1999) 
and to promote CRE-dependent gene transcription 
in rat brain (Duman 2004). This transcription factor 
is essential for the proper TH gene regulation in 
the adrenal gland (Sabban et al. 2004). Besides this 
signaling pathway, Shinkai et al. (2007) reported that 
milinacipran, a serotonin norepinephrine reuptake 
inhibitor, activates TH through a p44/42 mitogen-
activated protein kinase (MAPK)-dependent pathway 
in cultured bovine adrenal medullary cells.
Our results show that VMAT2 and NET 
mRNA levels are reduced in rats exposed to CUMS. 
Tillinger et al. (2010) have recently observed that 
VMAT2 is up-regulated in chromaffin cells in vivo 
following immobilization stress. The differences 
of these and our results related to VMAT2 gene 
expression could be ascribed to the differences in 
the types of stress paradigms. On the other hand, our 
finding of reduced NET mRNA levels in medulla 
of chronically stressed rats agrees well with that of 
Cubells et al. (1995) who reported that reserpine-
induced activation led to increased TH mRNA 
levels but at the same time to a significant decrease 
in NET mRNA levels both in locus coeruleus and 
adrenal medulla. Wakade et al. (1996) provided 
the evidence that glucocorticoids decreased NET 
mRNA and functional activity in rat chromaffin 
cells maintained in culture, primarily through the 
changes in activator protein-1 (AP-1) motif/binding 
protein interactions. Reduced expression of these 
transporters could result from increased demand 
for catecholamine secretion, because it would 
decrease the reuptake of NE and thus enhance NE 
release into the circulation. Finally, the observed 
opposite TH and NET gene expression regulation 
in the adrenals of CUMS rats would be anticipated 
to contribute to the maintenance of stress response.
Yasumoto et al. (2009) suggested that fluoxetine 
was able to deplete catecholamines by inhibiting 
the activity of VMAT2. However, our results did 
not indicate the impact of this drug on the gene 
expression of VMAT2 transporter. In the present 
experiments we detected a significant decrease in 
NET mRNA after chronic fluoxetine treatment. This 
is the first direct evidence clearly demonstrating the 
effect of fluoxetine on gene expression of NET in 
rat adrenal medulla. These results indicate that we 
should not exclude the possibility that the inhibition 
of NE uptake, contributes to the increased NE 
concentration in plasma, induced by fluoxetine. 
Rodent NE transporter promoter does not possess 
a cAMP response element, but it does have an 
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AP-1 site (Fritz et al. 1998) and immediate-early 
gene products that bind to this site (Fos and Jun) 
and can be induced by cAMP (Herdegen 1996). 
Direct treatment of bovine adrenal chromaffin 
cells in vitro with the agents that elevate or mimic 
intracellular cAMP was reported to reduce NE 
uptake (Bunn et al. 1992). Besides, nerve growth 
factor (NGF) and other neurotrophins were 
also present in developing and mature adrenal 
chromaffin cells (Suter-Crazzolara et al. 1996). 
After treatment of rat pheochromocytoma cell line 
PC12 with NGF, Ikeda et al. (2001) demonstrated 
decreased NET mRNA, but increased TH mRNA 
levels. On the other hand, chronic application of 
fluoxetine led to NFG enhancement in the frontal 
cortex (Hassanzadeh and Hassanzadeh 2009).
Amplifying catecholaminergic signaling, obser-
ved after fluoxetine treatment, could be associated 
with cardiovascular side effects. Rotondi et al. (2011) 
reported the clinical case in which duloxetine may 
have precipitated "tako-tsubo" cardiomyopathy by 
increasing plasma catecholamine concentration. 
Considering the fact that we have recently also 
recorded a significant increase of β1-adrenoreceptor 
mRNA levels in the heart of CUMS rats treated with 
fluoxetine (Spasojevic et al. 2011), these findings 
should be taken into account when treating depressed 
patients with concomitant cardiac disease. Further 
studies are necessary to confirm our data and establish 
the functional significance of these results.
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RESUMO
Mostramos recentemente que o tratamento crônico com 
fluoxetina agiu de forma a aumentar significativamente 
as concentrações de noradrenalina e adrenalina no plasma 
tanto nos controles quanto em ratos machos adultos 
cronicamente estressados. No entanto, os possíveis efeitos 
da fluoxetina na síntese de catecolaminas e recaptação 
na medula adrenal são em grande parte desconhecidos. 
No presente estudo, os efeitos do tratamento crônico 
com fluoxetina sobre a tirosina hidroxilase, uma enzima 
limitante da velocidade de síntese de catecolaminas, 
bem como a expressão gênica de um transportador 
de norepinefrina e do Transporter 2 de monoamina 
vesicular na medula adrenal foram investigados em 
animais expostos ao estresse leve crônico imprevisível 
(CUMS) durante 4 semanas. Análises de expressão 
gênica foram realizadas utilizando transcrição reversa-
PCR quantitativa em tempo real. Animais com estresse 
crônico tiveram níveis aumentados de mRNA para 
tirosina hidroxilase e a expressão diminuída de ambos 
os transportadores. A fluoxetina aumentou a tirosina 
hidroxilase e diminuiu a expressão do gene transportador 
de norepinefrina tanto em ratos não estressados quanto 
em CUMS. Estes resultados sugerem que o tratamento 
crônico com fluoxetina aumentou os níveis plasmáticos 
de catecolaminas por afetar alterações opostas na síntese 
e absorção de catecolaminas.
Palavras-chave: medula adrenal, antidepressivos, 
expressão gênica, transportador de norepinefrina, 
tirosina hidroxilase.
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